Ambry Genetics, A Konica Minolta Company  

Aliso Viejo,  CA 
United States
http://www.ambrygen.com
  • Booth: 641


The world would be better if human disease was understood.

Profile

We are a lab with a long history of firsts. First to offer exome services. First and only to participate and lead a study powered to verify that confirmation testing is essential for accurate results. First to invest in the building of a super lab, ensuring highly accurate test results and increased efficiencies. First to self-fund a platform designed to give away our data in a mission to understand disease better through AmbryShare. But it’s not our 'firsts' that set us apart. It’s our mission to put patients and understanding of genetics above all else.

WE ARE DRIVEN TO GIVE HEALTHCARE PROVIDERS THE MOST ADVANCED TESTING INFORMATION AVAILABLE SO YOU CAN DETERMINE THE BEST TREATMENT OPTIONS FOR YOUR PATIENTS


 Products

  • +RNAinsight
    Working in tandem with Ambry Genetics’ DNA testing,+RNAinsight improves the sensitivity and clarity of genetic testing....

  • +RNAinsight

    DNA-Only Testing May Miss Patients At-Risk For or With Hereditary Cancer

    Many patients suspected to have hereditary cancer receive negative or inconclusive results due to limitations of DNA-only genetic testing. While there have been several advancements in genetic testing since the days of Sanger sequencing, there is still a need to enhance variant detection and interpretation. Adding simultaneous RNA genetic testing to DNA-only tests with +RNAinsight is the next step to providing more accurate, actionable results to patients and their families.

    Paired DNA and RNA Testing Improves Variant Detection and Classification

    Add RNA genetic testing to a hereditary cancer panel for every patient undergoing DNA testing to deliver more clinically actionable results.

    Identify More Patients with Hereditary Cancer

    Find Patients That May be Missed by DNA-Only Testing

    Clinical diagnostic labs typically apply a reporting range limit to their DNA genetic testing panels. Variants outside these ranges have a much lower probability of being pathogenic (disease-causing) and would most often be classified as a variant of unknown significance (VUS). Looking beyond these ranges would only increase the VUS rate without increasing the diagnostic yield. However, using +RNAinsight expands the reporting range of DNA-based testing, which in turn enables Ambry to provide a clear diagnosis to more patients who may otherwise be missed.